GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

Conditions: Type2 Diabetes; Kidney Diseases
Interventions: Drug: Exenatide Extended Release for Inj Susp 2 MG; Drug: Placebo
Sponsors: University at Buffalo; AstraZeneca
Terminated

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 17, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments